Home/Pipeline/Emeramide for COPD

Emeramide for COPD

Chronic Obstructive Pulmonary Disease

Phase 2Active

Key Facts

Indication

Chronic Obstructive Pulmonary Disease

Phase

Phase 2

Status

Active

Company

EmeraMed

About EmeraMed

EmeraMed is a private, clinical-stage biotech developing Emeramide, a unique dithiol compound with antioxidant and metal-chelating properties. Its primary focus is on obtaining marketing authorization for treating mercury toxicity, supported by completed Phase 2 trials demonstrating safety. The company is also exploring applications in other conditions like COPD and COVID-19, where oxidative stress and iron dysregulation play a role, though these are in earlier stages of investigation.

View full company profile

Therapeutic Areas

Heavy Metal Toxicity COPD Infectious Disease

Other Chronic Obstructive Pulmonary Disease Drugs

Drug	Company	Phase	Status
Technegas® for COPD	Cyclomedica	Phase 2	Active
Autologous Stem Cell Therapy for COPD	STEMGENICS	Phase 2	Active
Meridigen‑COPD	Meridigen Biotech	Preclinical	Active
Novel Anti-inflammatory for COPD	Shenzhen Salubris Pharmaceuticals	Phase I/II	Active
F528	Gyre Therapeutics	Not Specified	Evaluated